Heart defects are among the most common birth defects and are the leading cause of birth defect-related deaths.
Through The Heart Center at Nationwide Children’s Hospital and the Center for Cardiovascular and Pulmonary Research at The Research Institute, clinicians and scientists work together to match questions developed at the bedside with answers evidenced at the benchside. These collaborative endeavors then deliver improvements back to the bedside, all in the name of enhancing patient care. This “boomerang” approach to translational research ensures that patients receive the latest advances in cardiac care at Nationwide Children’s Hospital.
Faculty members conduct patient-centered research projects in cardiology and cutting-edge basic science in cardiovascular and pulmonary medicine. For example, Nationwide Children’s Hospital is the only hospital in the country conducting pediatric translational research on individual heart cells. Get the latest Heart Center research and innovation.
Late 2009, Nationwide Children’s Hospital and The Ohio State University received a five-year, National Institutes of Health, National Heart, Lung and Blood Institute grant to provide in-depth training to clinicians and basic scientists in congenital and acquired heart disease. This training program is the first in the country that focuses on cardiovascular disease as a continuum from fetal life to senescence.
Clinical researchers at Nationwide Children's Hospital are committed to identifying new approaches for the prevention, diagnosis and treatment of childhood diseases, taking research discoveries from the lab to the patient's bedside.
Browse current Cardiology research studies being conducted at Nationwide Children’s Hospital
Adult Congenital Heart Disease
Surgical Palliation and Device-Based Therapies
Genetics of Congenital Heart Disease
The Heart in Neuromuscular Disease
Outcomes-Based Cardiology Research
Randomized, controlled trial of early versus delayed umbilical cord clamping in infants with congenital heart disease, American Heart Association (Carl Backes, 7/2/14 – 7/1/15) $60,500
Gore Helex Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging – Confirmed TIA in Patients with Patent Foramen Ovale (PFO), The Gore Reduce Study, Gore Medical (Ralf J. Holzer, MD, PhD)
Center for Cardiovascular and Pulmonary Research
Research Study: Genetic Testing of Individuals & Families with Congenital Heart Disease